Drugs / Standard Plasma
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04372979 Comparator | Sep 2020 → Jun 2021 | COVID-19 | Central Directorate of the Army Health Service | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Standard Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04372979 ↗ |
| Modality | Protein / enzyme biologic | “2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.” NCT04372979 ↗ |
| Route | Intravenous | “Subjects will receive an intravenous injection of standard Plasma.” NCT04372979 ↗ |